Synonym
Deramciclane fumarate; Deramciclane; EGIS 3886; EGIS-3886; EGIS3886; exo-EGYT 3886;
IUPAC/Chemical Name
N,N-dimethyl-2-(((1R,2S,4R)-1,7,7-trimethyl-2-phenylbicyclo[2.2.1]heptan-2-yl)oxy)ethan-1-amine fumarate
InChi Key
RFQWRWCCNQNACG-HJYQBBATSA-N
InChi Code
InChI=1S/C20H31NO.C4H4O4/c1-18(2)17-11-12-19(18,3)20(15-17,22-14-13-21(4)5)16-9-7-6-8-10-16;5-3(6)1-2-4(7)8/h6-10,17H,11-15H2,1-5H3;1-2H,(H,5,6)(H,7,8)/b;2-1+/t17-,19-,20+;/m1./s1
SMILES Code
O=C(O)/C=C/C(O)=O.CC1(C)[C@@]2([H])C[C@](OCCN(C)C)(C3=CC=CC=C3)[C@]1(C)CC2
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
417.55
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Kääriäinen TM, Lehtonen M, Forsberg MM, Savolainen J, Käenmäki M, Männistö PT. Comparison of the effects of deramciclane, ritanserin and buspirone on extracellular dopamine and its metabolites in striatum and nucleus accumbens of freely moving rats. Basic Clin Pharmacol Toxicol. 2008 Jan;102(1):50-8. Epub 2007 Oct 25. PubMed PMID: 17971064.
2: Al-Behaisi S, Antal I, Morovján G, Marton S, Klebovich I. The effect of oil as a dietary component on in vitro dissolution of an acid-labile drug. Pharmazie. 2003 Jul;58(7):502-3. PubMed PMID: 12894756.
3: Nemes KB, Abermann M, Bojti E, Grézal G, Al-Behaisi S, Klebovich I. Oral, intraperitoneal and intravenous pharmacokinetics of deramciclane and its N-desmethyl metabolite in the rat. J Pharm Pharmacol. 2000 Jan;52(1):47-51. PubMed PMID: 10716602.
4: Ladányi L, Sztruhár I, Budai Z, Lukács G, Mezei T, Argay G, Kálmán A, Simig G. Stereochemistry and enantiomeric purity of a novel anxiolytic agent, deramciclane fumarate. Chirality. 1999;11(9):689-93. PubMed PMID: 10506429.
5: Kanerva H, Vilkman H, Någren K, Kilkku O, Kuoppamäki M, Syvälahti E, Hietala J. Brain 5-HT2A receptor occupancy of deramciclane in humans after a single oral administration--a positron emission tomography study. Psychopharmacology (Berl). 1999 Jul;145(1):76-81. PubMed PMID: 10445375.
6: Lengyel J, Bolehovszky A, Klebovich I, Aberman M, Magyar K. Absorption of the new anxiolytic compound deramciclane in rats, dogs and rabbits. Arzneimittelforschung. 1998 May;48(5):455-60. PubMed PMID: 9638311.
